Programme : Presentations by Time

Tuesday, 6 October 2020

Tue6  Oct11:00am(30 mins)
Pelago Bioscience AB
Platinum Sponsor Presenters - Stina Lundgren & Michael Dabrowski Title - Navigate your chemistry and explore your biology with CETSA Abstract - Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. Applying CETSA®, drug discovery R&D companies can make better and more informed decisions at earlier stages in their projects. Welcome to learn about the targeted formats in CETSA Navigate, and the proteome-wide mass spectrometry-based method CETSA Explore. We will present the application of CETSA® in primary screening, hit confirmation, target deconvolution, and toxicology safety assessment studies.
Tue6  Oct12:05pm(15 mins)
Industry Insider Presentation Presenter - Louise Affleck, PhD Title - PerkinElmer’s Reagents + Microplates for Drug Discovery Abstract - PerkinElmer has developed assay technologies, microplates and multi-mode plate readers for Drug Discovery research. The HTRF and AlphaLISA homogeneous, and the DELFIA orthogonal assay platforms are robust and flexible and can be applied to a large range of drug targets and disease areas (e.g. Oncology, Immuno-Oncology, AutoImmunity, Neurosciences, Inflammation and Fibrosis) for small and large molecule drug research. This presentation highlights: • Biochemical PPI assays for COVID-19 therapeutic discovery. • GPCR functional and binding assays. • Cell based signalling phospho-protein assays. • Cytokine release quantification assays. • Biochemical Kinase Activity + Binding Assays. • Epigenetics assays.
Tue6  Oct01:30pm(30 mins)
Sartorius Stedim Biotech
Workshop Presentation - Technologies and solutions for the development of novel biopharmaceuticals – from molecule identification to cell line development Numerous tools currently exist to facilitate the identification of potential candidate molecules to be selected for further preclinical testing. However, high subsequent clinical attrition rates are commonplace due to the poor efficacy and safety of many such molecules. Innovative new tools and technologies are therefore required to aid early stage decision-making in order to identify the best performing candidates to ensure low subsequent clinical study failure rates. This presentation will focus on recent advances in the field of live-cell imaging and analysis, high-throughput screening, and biomolecular interaction analysis in order to derive a deeper understanding of critical biological functions and drug effects. These powerful tools provide new insights to ensure that the most appropriate candidate molecule is identified using physiologically relevant methods and the fastest path to actionable result during the complex drug development process. Speakers: Dr Helge Schnerr, Senior Marketing Manager EMEA ,FortéBio ( A Sartorius Brand) Matthew Tomlinson, BioA FAS Manager, EMEA, Sartorius
Tue6  Oct02:00pm(15 mins)
Sygnature Discovery
Industry Insider Presentation Presenter - Dr Stephen Young (VP Business Development) Title - Building a modern screening library and infrastructure Abstract - Many organisations have inherited a legacy library and screening infrastructure which in some cases has been tweaked to reflect modern thinking on lead-like properties and toxicity liabilities or improved informatics. At Sygnature we have been fortunate to be able to start with a clean slate and choose informatics and automation systems and select library compounds to provide a high diversity, high fidelity screening capability. Here we present the key components of our latest addition to our hit identification capabilities.
Tue6  Oct04:00pm(5 mins)
Thermo Fisher Scientific
Technology Spotlight Presentation Presenter - Nikolaus Machuy Title - Increase your hits with laboratory automation Abstract - Learn about the various routes to successfully automating scientific workflows with an emphasis on drug discovery applications and maximizing the quality of your hits. Understand the latest in collaborative automation and explore the innovative technology and features of our powerful scheduling software that help scientists accelerate their productivity.
Tue6  Oct04:05pm(5 mins)
Genedata AG
Technology Spotlight Presentation Presenter - Mark Brewer Title - Genedata Screener: Automating Complex Assay Analysis and Integrating Results for Pre-clinical Drug Discovery Abstract - One important strategy to create better hits in pre-clinical drug discovery is to characterize molecules more thoroughly via arrays of experiments at earlier stages in the process. Of high importance are readouts which elucidate mechanism of action and kinetic properties, which allow for a more informed and systematic progression towards leads and potentially the delivery of superior clinical candidates. Here, we present an enterprise data analysis platform - Genedata Screener – which captures, analyses, and manages all pre-clinical screening data across diverse assay technologies and instrumentation. Screener software harmonizes complex data analytics while automating repetitive steps, preparing ready-to-use result sets for scientists to assess with their own expertise and take project decisions. We highlight examples how this solution automates complex analytical decisions in modern mechanistic and kinetic-based assays, thus enabling their analysis at scale. For progression decisions, these results then are integrated with results from other key experiments, showcasing the importance of a consolidated data analytical solution for improved pre-clinical research.
Tue6  Oct04:10pm(5 mins)
Promega UK Ltd
Technology Spotlight Presentation Presenter - Dr Lucy Wheatley, Promega UK Title - Lumit™ Technology for Homogeneous Bioluminescent Immunoassays’ Abstract

Wednesday, 7 October 2020

Wed7  Oct11:25am(15 mins)
Q&A session
Wed7  Oct11:40am(15 mins)
Charles River
Industry Insider Presentation Presenter - Darren Matthews BSc PhD – Research Leader Title - Use of the Developability Classicisation System to guide early stage development projects Abstract - Less than 5% of potential candidates make it through preclinical studies to a positive Phase III outcome. A significant contributor to this high attrition rate is a lack of efficacy as a result of poor bioavailability. In the past decade ‘simple’ tools, such as the Developability Classification System (DCS), have been proposed to reduce this attrition rate. In recent years the DCS has been successful at aiding formulation scientists developing formulation strategies for clinical studies. Utilization of the DCS earlier in development programme (i.e. Hit to lead and Lead Optimization) has aided and understanding of potential bioavailability challenges, guide development strategies and aid candidate nomination. An example of how the DCS was used to highlight potential challenges with a nominated compound and enabled a suitable strategy to be undertaken to ensure successful preclinical studies is presented.
Wed7  Oct01:50pm(15 mins)
Q&A session
Wed7  Oct02:05pm(15 mins)
Beckman Coulter UK Ltd.
Industry Insider Presentation Presenter invited by Beckman - Olivier Casamitjana Title - Evotec Sample management: Evolution of our processes towards acoustic tube technology Abstract - Evotec is one of the leaders in Sample Management activities. Recently, Evotec Sample Management decided to invest in the acoustic tube technology to support the plate preparation processes for HTS projects. The team have launched a project to assess the impact on this change in our organization along the value chain. In addition, to validate the use of this new technology in the Evotec environmental condition, the Sample Management has also launched a 1-year experimental plan on commercial compounds in order to assess the impact on the integrity of these compounds after several freezing / thawing cycles.
Wed7  Oct02:20pm(60 mins)
Pelago Bioscience AB
Hot Topic Discussion - Overcoming challenges in early lead generation - how to get ahead in drug discovery
Wed7  Oct04:10pm(15 mins)
Q&A Session

Thursday, 8 October 2020

Thu8  Oct10:40am(30 mins)
Promega UK Ltd
Platinum Sponsorship Presentation Presenter - Dr Leigh Stoddart Title - Fluorescence and bioluminescence approaches to study the adenosine A2A receptor Abstract - From a structural point of view, the adenosine A2A receptor (A2AAR) is one of the most studied G protein-coupled receptors with over 30 X-ray crystal structures solved in complex with molecules with a range of efficacies. This wealth of structural information has informed the rational design of ligands for this receptor to be used in a number of therapeutic settings including immuno-oncology and Parkinson’s disease but so far, their success in the clinic has been limited. A number of the early signalling events trigged by the A2AAR including βarrestin recruitment and internalisation are poorly understood. To perform detailed, real-time, pharmacological studies of this receptor requires high affinity and sub-type selective fluorescent probes. This talk will discuss the characterisation of fluorescent agonist and antagonists for the study of the A2AAR, with an emphasis on the development of sub-type selective fluorescent antagonists guided by molecular modelling. I will then discuss a new approach to label the A2AAR in which a fluorophore can be transferred covalently to the A2AAR. In this method, the fluorescent ligand contains a reactive group between the fluorophore and the pharmacophore (antagonist) and when bound to the receptor, the reactive group can form a covalent bond with nearby nucleophilic amino acids. I will also demonstrate that pharmacophore can dissociate from the binding pocket, allowing the receptor to be probed with further ligands. Finally, using a number of techniques we have found that the A2AAR does not internalise in response to agonist treatment and does not recruit βarrestin and I will discuss how we can use our fluorescent ligand technology to investigate this further.
Thu8  Oct12:15pm(60 mins)
Poster Session
Thu8  Oct02:45pm(15 mins)
Industry Insider Presentation Presenter - Pankaj Garg Title - A High Throughput Platform to Develop Highly Potent and Functional Antibodies Against G-Protein Coupled Receptors Abstract - Listen to Pankaj Garg, PhD, Senior Scientist at Twist Bioscience present a poster that describes the construction of a GPCR-focused phage-display antibody library. You will also hear how mining GPCR binding ligands and peptides and by incorporating their sequences into heavy chain CDR3, Twist Bioscience was able to develop a design for identifying functional antibodies to a range of GPCR targets.

Friday, 9 October 2020

Fri9  Oct10:35am(5 mins)

Presenter - Joanne Walter, Global Sales Director LenioBio GmbH Title - ALiCE®: Fast and scalable solutions to accelerate research Abstract - ALiCE® is the first scalable, eukaryotic cell-free protein-expression platform that will fundamentally change how you approach protein expression (peptides, enzymes, antibodies, virus like particles) It will disrupt conventional protein production and accelerate research. ALiCE® combines the best properties of cell-based and cell-free, eukaryotic systems, making it a versatile, scalable protein production system – Fast, Flexible and Ready to go.
Fri9  Oct11:10am(5 mins)
Presenter - Brian E. Hall Amnis Imaging Flow Cytometer product manager Title-Methods in Imaging Flow Cytometry Data Analysis
Fri9  Oct01:00pm(15 mins)
Presenter - Peter Coombs Title - Fragment Based Target Screening – An empirical approach to prioritizing antibacterials targets Abstract - New antibacterial drugs are urgently needed to tackle the emerging crisis of multidrug-resistant infections. Functional genomic data, for example from transposon mutagenesis studies, can generate lists of potential new druggable targets including novel ‘clinically naïve’ antibacterial targets with untapped potential, though these targets represent a much higher risk proposition due to limited target characterisation and validation. Identifying therapeutically relevant targets and prioritising the most druggable presents a challenge. Bioinformatic approaches and literature diligence are valuable tools but struggle to build confidence in novel targets. In addition, there are two key aspects to target selection that are best examined empirically: tractability and ligandability. At LifeArc, we have developed a high-throughput fragment screening approach we call Fragment Based Target Screening (FBTS) to examine this. 50 potential targets were selected by bioinformatic analysis from a TraDIS dataset of essential genes from our collaborators at DSTL. Our high-throughput expression and purification platform was used to test the targets for expression. Following biophysical quality control checks, 38 proteins were screened against a library of 1280 fragments on a Biacore 8K, then hits confirmed in dose-response experiments. Automated data-processing and machine learning were applied to assign a ligandability score to each target & prioritise hits for progression. This was combined with additional essentiality data & a progression assessment to compile a priority list of targets to advance into drug discovery projects. The FBTS empirical triage process is an efficient way to make evidence-based decisions for a large set of targets, allowing exploration of novel antibacterial targets with room for attrition to focus efforts on more tractable options. Targets that are proven to behave well and bind a large range of fragments with the greatest affinity are excellent starting points for drug discovery development.

Tuesday, 13 October 2020

Tue13  Oct10:10am(30 mins)

Platinum Sponsor Presenters -Dr Thomas Moreau, Head of Research, Kam Dhaliwal, SVP Alliance Management, Title - Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery Abstract - Advances in cellular reprogramming have opened up new doors for studying human health and disease, drug discovery, and the development of cell therapies. Widespread use of human-induced, pluripotent stem cell (hiPSC)-derived, mature cell types however, is restricted by complex differentiation protocols and inefficient reprogramming methods. is a human synthetic biology enterprise based in Cambridge, UK, developing a scalable technology platform capable of producing consistent and functional batches of every human cell. cellular reprogramming technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.
Tue13  Oct11:15am(15 mins)

Industry Insider Presentation Presenter - Athanasia Apostolou Title - A human-based micro-engineered Colon Intestine-Chip to study mechanisms that drive epithelial barrier disruption and restitution. Abstract - The leaky-gut syndrome is implicated in the progression of a number of inflammatory diseases, while it consists a side effect of various classes of drugs. However, the limited number of available experimental models to study human intestinal epithelial biology, further imped the development of efficient therapeutics. We combined advancements on the organoid and Organ-on-Chip technologies to develop a microengineered, human Colon Intestine-Chip platform that allows the establishment of a colonoids derived epithelial monolayer with tissue reminiscent cytoarchitecture and transcriptome profile. Leveraging IFNγ, a cytokine hallmark of the progression of intestinal inflammation, we establish a reproducible cytokine-mediated barrier disruption, driven by induction of apoptosis and reorganization of the apical junctional complexes as previously described, an effect rescued by the presence of the JAK3 inhibitor, Tofacitinib. Our data also suggest a novel mechanism of action of IL-22 on mature intestinal epithelial cells, that contradicts the predominantly described beneficial role of the cytokine in experimental models of colitis. The Colon Intestine-Chip could enable the investigation of novel mechanisms driving the leaky gut syndrome and enable their translation from bench to patient bedside.
Tue13  Oct01:30pm(15 mins)
UPM Biomedicals
Industry Insider Presentation Presenter - Lauri Paasonen Title - Advanced Three Dimensional Cell-Based Assays for Drug Screening and Toxicity Studies Abstract - Introduction More biologically relevant in vitro cell models with improved functionality are needed for disease modelling and cell-bas
Tue13  Oct02:15pm(60 mins)

Hot Topic Discussion - Solving the R&D efficiency conundrum within Drug Discovery: Thoughts, Insights and Solutions Panelists - 1. Steve Rees - Vice President Discovery Biology, AstraZeneca 2. Benedict Cross - Chief Technology Officer, PhoreMost 3. Tilmann Buerckstuemmer- Cheif Scientific Officer, Aelian 4. Marijn Vlaming- Head of Biology for the Beerse (Belgium) and Leiden (The Netherlands), Charles River Laboratories 5. Kam Dhaliwal-Senior VP Alliance Management,
Tue13  Oct03:45pm(5 mins)
Presenter - Sanj Kumar, CBO, Atelerix Ltd Title - Ensuring your cell based models remain relevant, by avoiding freeze-thaw; Atelerix’s encapsulation technology for room temperature storage and shipping of cells & tissues. Abstract - Atelerix's innovative hydrogel technology allows for storage and transport of human cells and tissues at room temperature, which will revolutionise cold-chain supply logistics of biological material. Our hydrogel matrix protects cells, by encapsulating them and this prevents their deterioration so they retain their activity for longer. Atelerix's hydrogel products use non-toxic materials, are GMP compatible and do not affect the safety of the biological sample. Our hydrogel technology is patented in Europe and USA, with additional applications pending worldwide. Thanks to our innovative technology, biological samples can be stored and shipped safely at room temperature without the need for cryo-shippers or specialised time-sensitive transport logistics, thus reducing its overall cost and preserving the relevance of your patient model.
Tue13  Oct03:50pm(5 mins)
Presenter - Joe Lackey Title - Clinically Relevant Models of Oncology Abstract - Clinically relevant models of oncology are crucial to advances in research from bench to bedside. ATCC has applied advanced techniques to develop relevant models for use in areas including translational research and screening, for pathways including EMT/MET, KRAS and MEK, across 2D and 3D patient-derived organoid models.
Tue13  Oct03:55pm(5 mins)
Miltenyi Biotec Ltd
Presenter - Kristina Kremer Title - Density-gradient-free solutions for cell isolation Abstract - : The current restrictions in laboratories worldwide caused by the Covid-19 pandemic have made it more important than ever before to optimize experimental workflows due to social distancing, working in shifts and reduced availability of fresh blood materials. Density-gradient centrifugation is time-consuming, labor-intensive, and the results vary depending on the user. Do you want to skip this process, follow all given Covid-19 regulations and get your experiments done to reach your 2020 goals? Miltenyi Biotec offers a large portfolio of Ficoll®-free options for primary cell isolation directly from human blood materials, including Leukopaks®, buffy coats, LRSCs and whole blood samples. Let’s have a glimpse at how to make your PBMC and immune cell isolations easier, faster and more economical, while improving reproducibility and user safety by automating your cell separation processes.

Wednesday, 14 October 2020

Wed14  Oct11:35am(15 mins)
BD Biosciences
Industry Insider Presentation Presenter - Dr Helen Smith Title - Next Gen Cytometry - increasing experimental power, reducing time to insights Abstract - Combine classic flow cytometric analysis and sorting with our novel RNA-seq based technology to simultaneously analyse over 100 proteins and tens of thousands of genes at a single cell level. Featuring a micro well capture based system for high throughput with sample multiplexing for immediate comparative analytics. Generate big data sets that feed into powerful Cloud based computing platforms supported by our market leading informatics support solutions to reveal deep insights fast.
Wed14  Oct01:50pm(15 mins)
Beckman Coulter UK Ltd.
Industry Insider Presentation Presenter invited by Beckman - Marc Emmenegger, University Hospital Zurich Title - SARS-CoV-2 seroprevalence in a large population
Wed14  Oct04:00pm(5 mins)
Presenter - Anna Oschowitzer, Field Application Specialist Title - Highly Efficient Miniaturization and Automation of Single-cell Omics Workflows Abstract - Performing high-throughput single-cell analysis on a routine basis requires robust instrumentation. At the same time, flexible platforms are needed that can accommodate a wide range of different assays. cytena provides an open and automated platform for plate-based single-cell analysis workflows, including single-cell RNA sequencing, single-cell genome sequencing, single-cell proteomics, as well as the latest assays for single-cell multiomics. Here, we present the f.sight™ for gentle, precise single-cell dispensing and the I-DOT™ for rapid non-contact liquid handling tasks and show how these tools improve single-cell omic workflows thereby advancing the future of drug discovery.

Thursday, 15 October 2020

Thu15  Oct10:05am(30 mins)
BioTek Instruments
Platinum Presentation Presenter - Dr. Charles William Amirmansour Title - The Multi-faceted Assays Enabled with Cytation Technology: An Advanced Tool for Smarter Target-Based, Phenotypic Research & Screening Abstract - This informative webinar will provide an overview of BioTek’s Hybrid Technology™, and its utilization to drive a multidisciplinary approach to target-based and phenotypic research and screening. This will include a diverse range of applications and workflow solutions including quantitative microscopy and biochemical-based assays utilized across the field of cancer research
Thu15  Oct11:05am(15 mins)
Charles River
Presenter - Sanne Holt, PhD; Group Leader Biology
Title - In vitro cell based cytotoxicity and T cell activation assays to assess safety and efficacy of engineered T cell therapies Abstract - CAR and T cell receptor engineered T cells are showing great promise in cancer clinical trials but a challenge remains with on-target tumor and off-target toxicities. We have developed in vitro assays utilizing primary human cells from healthy tissue and/or differentiated iPCS-derived cells to assess on-target off-tumor and/or off-target cytotoxicity for engineered T cell therapies. The developed safety assays provide a robust and rapid platform to assess cytotoxicity effects within immuno-oncology therapies, either TCR or CAR-T cells, in both early stage development or late stage testing of the therapeutic product.
Thu15  Oct02:20pm(5 mins)
Presenter - Nirmal Perera Title - Next Generation Cancer Models from the HCMI Abstract - At present cancer research is limited by the lack of effective pre-clinical research models which model the disease effectively. Cell lines used in cancer research are limited by the lack of heterogeneity, clinical outcome data or genetic data associated with them. The cancer organoid models as well as the clinical 2-D cancer models provided by ATCC are polyclonal in nature; have associated genetic and clinical outcome data and are more accurate representations of cancer models.
Thu15  Oct02:25pm(5 mins)
Yokogawa Deutschland GmbH
Presenter - Professor Aline F. Miller, Chief Executive Officer and Founder Title - Building 3D healthy and tumour tissue models using peptide hydrogels.
Thu15  Oct02:30pm(5 mins)
Presenter - Dr. Owen Hughes Amnis Sales specialist Title - Amnis Imaging Flow Cytometry for deeper insights into mechanisms of action
Thu15  Oct02:35pm(60 mins)

Hot Topic Discussion - How to get the most from your oncology sample by going centrifuge free. We will discuss applications for bead immunoassays, flow, mass cytometry and single cell genomics
Thu15  Oct04:00pm(15 mins)
GE healthcare
Presenter -Mark Graham, PhD Title - Cytiva & Cell DIVE for Cancer Research: Highly Multiplexed Immunofluorescent Imaging of tissue sections for spatial subcellular analysis Abstract - A dedicated Cell DIVE Imager was released in the UK in 2020 but the underlying technology has been in development for decades. This development culminated in the first publication in 2013, where Gerdes et al successfully imaged 60 different proteins on the same slide. This was achieved by a process known as highly multiplexed immunofluorescence (HMxIF). Since the 2013, many publications using HMxIF have shown the importance of not just expression, but the spatial context of the cell population in the tumour microenvironment. Cell DIVE provides this insight along with the opportunity to conduct sub cellular segmentation and analysis. Cell DIVE for HMxIF is another research tool which Cytiva has added to its battery of hardware for cancer research.

Friday, 16 October 2020

Fri16  Oct11:05am(30 mins)

Presenter - Curiox Biosystems, Charles River, Adicet Bio and more. Title - Curiox Biosystems hosts “Biology at its best for all modalities” Abstract - The complexity of disease continues to drive new and innovative modalities to tackle them. As our understanding of mechanism increases it provides new challenges and opportunities to improve legacy techniques. Effective analysis of biological change and response starts with the quality of the sample that is finally analysed. Consistency in sample processing workflow, minimising sample manipulation and cell stress results in better data. By eliminating the Centrifuge, Curiox customers continue to improve workflows and results for cytometry and single cell genomics. Three global companies detail their benefits of going centrifuge free in different modalities. 30 minutes will change the way you work forever: 1. Discovery oncology: Charles River. Improved cell recovery from low sample volumes for immunophenotyping. 2. Single cell genomics. Curiox et al. Standardising sample prep and increasing cell retention for single cell proteogenomic analysis. 3. Cell gene therapy-Analytical development and Q.C: AdiCet Bio. Improving workflow and consistency for Gamma delta (γδ) T cell products.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021